These conclusions suggest that CYLD can be used as a clinical biomarker for predicting NPC prognosis, and that PFKFB3 may also be a new therapeutic target for targeted therapy in the future (56). This evidence concerns the gene PFKFB3 and nasopharyngeal carcinoma.